dose
Expressed as a combination of ticarcillin (as sodium salt)
and clauvulanic acid (as potassium salt) in a ratio of 15:1.
By I.V infusion, 3.2 g every 6-8 hours increased to every 4 hours in more severe infections; C
hild 1 month-18 years, body-weight under 40 kg, 80 mg/kg every 8 hours,
increased to every 6 hours in more severe infections; body weight over 40 kg, adult dose.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Timentin | GlaxoSmithkline | GlaxoSmithKline | 3.0g/0.2g | 4 | Injection | per vial | KES 10,897.30 |
| Mode Of Action | interfere with the synthesis of peptidoglycans, which are part of bacterial cell wall (bactericidal). Sulbactam is a beta-lactamase inhibitor |
|---|---|
| Drug Indication | Bacterial septicaemia, RTI, skin and soft tissue infections, intra-abdominal infections, infections of female pelvis and GU, complicated UTI, severe infections due to pseudomonas, proteus and E.coli. |
| Precautions | Hypersensitivity reactions to penicillin and / or cephalosporins, parenteral solutions should not be injected into or near an artery or nerve. |
| Contra-Indications | Hypersensitivity reactions to penicillin and / or cephalosporins, parenteral solutions should not be injected into or near an artery or nerve. |
| Side Effects | Hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction; rarely CNS toxicity including convulsions (especially with high doses or in severe renal impairment), interstitial nephritis, haemolytic anaemia, leucopenia, thrombocytopenia and coagulation disorders; also reported diarrhoea (including antibiotic-associated colitis). Also nausea, vomiting, coagulation disorders, haemorrhagic cystitis (more frequent in children), inj |
| Dosage | Expressed as a combination of ticarcillin (as sodium salt) and clauvulanic acid (as potassium salt) in a ratio of 15:1. By I.V infusion, 3.2 g every 6-8 hours increased to every 4 hours in more severe infections; child 1 month-18 years, body-weight under 40 kg, 80 mg/kg every 8 hours, increased to every 6 hours in more severe infections; body weight over 40 kg, adult dose. |
| Special Information | A combination of carboxypenicillin active against pseudomonas and other gram negative bacteria and a beta-lactamase (clavulonate) inhibitor. carboxypenicillin interferes with the synthesis of peptidoglycans, which are part of bacterial cell wall (bactericidal). |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Penicillins |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Timentin | GlaxoSmithkline | GlaxoSmithKline | 3.0g/0.2g | 4 | Injection | per vial | KES 10,897.30 |